Freeze-Induced Betaine Loading Enhances Lipid Nanoparticle mRNA Delivery

Study Background and Research Question

Lipid nanoparticles (LNPs) have become the leading nonviral carriers for messenger RNA (mRNA) therapeutics, most notably in the rapid deployment of mRNA vaccines against COVID-19. Despite their clinical success, a persistent challenge is the inherent instability of mRNA, which is prone to hydrolysis, oxidation, and enzymatic degradation. This necessitates stringent cold-chain storage and the use of cryoprotectants (CPAs) to preserve LNP integrity during freezing and thawing cycles. However, freeze-thaw (F-T) processes themselves can introduce additional risks: ice crystal formation and osmotic stress may cause LNP fusion, aggregation, and leakage of encapsulated mRNA, ultimately reducing delivery efficacy. The research question addressed by Cheng et al. (2025) is whether the freeze-thaw process can be leveraged not merely as a challenge to be mitigated, but as an opportunity to enhance LNP functionality by actively incorporating beneficial CPAs such as betaine into the LNP structure.

Key Innovation from the Reference Study

The central innovation of the study is the discovery that during freezing, the process of freeze concentration—where solutes are excluded from the forming ice and become highly concentrated in the remaining liquid—creates steep concentration gradients across the LNP membrane. This environment facilitates the passive diffusion of small molecule CPAs like betaine into LNPs. By incorporating betaine during the F-T process, the authors demonstrate that betaine acts not only as a conventional cryoprotectant but also as an active modulator of LNP structure and function. The betaine-loaded LNPs show improved endosomal escape and enhanced mRNA delivery efficacy, leading to stronger immune responses in vivo. This approach reframes the F-T process from a limitation to a formulation strategy for next-generation mRNA-LNP therapeutics (reference).

Methods and Experimental Design Insights

To elucidate the mechanism and impact of betaine incorporation, the authors prepared mRNA-loaded LNPs and subjected them to freezing and thawing in the presence of various CPAs: sucrose, trehalose, and betaine. They characterized the size distribution, polydispersity index, and encapsulation efficiency of LNPs before and after F-T cycles using dynamic light scattering and biochemical assays. The degree of CPA incorporation was quantified, and the physicochemical changes in LNPs were monitored. For functional assessment, the team used a bioluminescent reporter mRNA—such as Firefly Luciferase mRNA—to measure in vitro and in vivo transfection efficiency via bioluminescence imaging, as well as immunogenicity assays in mice to evaluate humoral and cellular responses post-administration.

Protocol Parameters

• mRNA-LNP formulation: Standard ionizable lipid, cholesterol, DSPC, and PEG-lipid ratios; encapsulate mRNA at ~0.05-0.2 mg/mL.
• Cryoprotectant concentration: Betaine at 200-500 mM during freeze-thaw; compare to equimolar sucrose and trehalose for controls.
• Freeze-thaw cycles: Rapid freezing at −80°C, followed by controlled thawing at room temperature; typically 1-3 cycles.
• In vivo imaging: Use bioluminescent reporter mRNA (e.g., Firefly Luciferase mRNA) to track expression post-injection; imaging at 4 h and 24 h after administration.
• Immunogenicity assays: Harvest sera and splenocytes from treated mice for antibody titers and T cell response measurements.

Core Findings and Why They Matter

Data from Cheng et al. demonstrate that freezing in the presence of betaine results in significant CPA enrichment within LNPs, as confirmed by quantitative assays. Unlike sucrose or trehalose, betaine's zwitterionic nature enables it to traverse the lipid bilayer during freeze concentration. Functionally, betaine-loaded LNPs display markedly higher mRNA delivery efficiency both in vitro and in vivo, as measured by increased bioluminescence and protein expression. Importantly, in immune-competent mice, LNPs formulated with betaine induced more robust humoral and cellular immune responses compared to conventional sucrose-protected LNPs, even at lower mRNA doses. These findings suggest that betaine not only stabilizes LNPs during cryopreservation but also enhances endosomal escape of mRNA, which is a critical barrier in cytosolic delivery. Thus, the freeze-thaw process, when properly controlled, can serve as a tool to introduce functionally active excipients into LNPs, amplifying both delivery and immunogenicity.

Comparison with Existing Internal Articles

Several internal analyses, such as "Firefly Luciferase mRNA (ARCA, 5-moUTP): Next-Gen Reporter" and "Firefly Luciferase mRNA ARCA Capped: Next-Gen Bioluminescent Reporter", highlight the importance of chemical modifications like ARCA capping and 5-methoxyuridine incorporation for enhanced mRNA stability and immune evasion. These articles discuss how such advancements facilitate reproducible gene expression assay workflows and in vivo imaging, paralleling the reference study's emphasis on formulation-driven improvements. The present study advances this field by showing that not only nucleotide chemistry, but also the physical process of freezing with specific CPAs, can modulate LNP performance. This expands the toolkit for optimizing bioluminescent reporter mRNA delivery, a theme echoed in "Firefly Luciferase mRNA: Robust Reporter for Next-Gen Assays", where the synergy between chemical and process innovations is emphasized.

Limitations and Transferability

While the benefits of freeze-induced betaine loading are compelling, there are several caveats. First, the study is performed primarily in preclinical (mouse) models, and the safety or efficacy of betaine in human LNP formulations remains to be fully established. Second, the precise range of compatible LNP and mRNA compositions, as well as the effect of repeated F-T cycles on long-term stability and delivery, warrant further investigation. The approach is likely most applicable to research and development settings where custom LNP formulation and rapid prototyping are possible. Additionally, the interplay between CPA structure, mRNA chemical modifications, and LNP lipid composition may yield variable results and should be empirically tested for each new application.

Research Support Resources

For researchers aiming to replicate or extend this workflow, high-quality bioluminescent reporter mRNAs are essential. Firefly Luciferase mRNA (ARCA, 5-moUTP) (SKU R1012, APExBIO) is designed for robust, reproducible gene expression and in vivo imaging applications, benefiting from ARCA capping and 5-methoxyuridine modifications for enhanced stability and low innate immune activation. This reagent is compatible with LNP encapsulation and freeze-thaw protocols, supporting applications in gene expression assays, cell viability studies, and imaging-based delivery validation. Incorporating such advanced mRNAs can streamline the evaluation of next-generation LNP formulation strategies, as demonstrated in the reference study.